Miracell Participates in KIMES Busan with “Smart Mcell 2,” a Cutting-Edge Stem Cell Medical Device
Miracell, a cutting-edge stem cell medical device, will participate in KIMES Busan with its “Smart Mcell 2.” [Edaily Reporter Lee Soon-yong] Stem cell company Miracell (CEO Shin Hyun-soon) participated in the medical device exhibition “KIMES 2021 BUSAN,” held at BEXCO in Busan from the 29th to the 31st of last month. KIMES is Korea’s largest medical device and hospital equipment exhibition. This is the fourth KIMES Busan exhibition,centered around Busan and encompassing Daegu, Ulsan, North Gyeongsang Province, and South Gyeongsang Province. KIMES is an event dedicated to improving public health, advancing medical technology, and revitalizing the local medical and hospital industries. It provides a glimpse into the changing medical industry in response to global trends, attracting approximately 10,000 visitors annually, including medical professionals, industry insiders, buyers, and dealers. Over 180 companies participated in this exhibition, showcasing the latest medical equipment and medical information. Among the over 3,000 cutting-edge medical devices on display,the most notable was Miracell’s “Smart Mcell 2.” Miracell’s “Smart M-cell 2,” a “bone marrow and blood stem cell extraction device with a centrifuge vessel capable of selective separation,” has received approval from the Ministry of Food and Drug Safety and was certified as a new medical technology by the Ministry of Health and Welfare in February 2021. This cutting-edge regenerative medical biodevice extracts large quantities of concentrated, automatically separated stem cells through centrifugation with minimal manipulation, representing the future of K-smart healthcare. With stem cells known to have infinite benefits in cartilage defects, pain management, preventive medicine, and overall healthcare, Miracell’s booth, which showcased the Smart M-cell 2, attracted the attention of numerous medical professionals and healthcare industry professionals. Founded in the medical industry in 1986, Miracell launched in 2009 as a stem cell specialist company. Miracell is leading the popularization of the stem cell market with its Smart Mcell 2, a cutting-edge bio-regenerative medical device developed using proprietary technology, based on accumulated expertise accumulated over many years. In addition to the Seoul metropolitan area, including Gangnam, Miracell has a large number of CGP hospitals and clinics in major cities nationwide, including Daejeon, Daegu, Gwangju, Ulsan, and Busan. These hospitals offer orthopedic, plastic, dermatological, urological, obstetrics and gynecological, and family medicine services. Miracell’s Cellpia Global Platform (CGP) shares stem cell medical technology through a network of member hospitals and clinics. CGP provides education, technology transfer, medical equipment setup, and marketing to ensure safer stem cell regenerative medicine treatments for hospitals both domestically and internationally. Through this KIMES Busan exhibition, Miracell signed contracts with numerous hospitals and clinics, expanding its market share to smaller cities in the Yeongnam region.
Hwasun International Vaccine Forum Opens, Attracting KRW 22.7 Billion in Investment from Pharmaceutical and Healthcare Companies
Hwasun International Vaccine Forum Opens, Attracting KRW 22.7 Billion in Investment from Pharmaceutical and Healthcare Companies Article SummaryInvestment Agreements Signed with Six Companies Specializing in Vaccines, Anticancer Drugs, and MoreHwasun to Be Developed as a Global Vaccine Hub and Bio-Base [Gwangju=Newsis] Reporter Gu Gil-yong = With the 2021 Hwasun International Vaccine Forum opening on the 4th, South Jeolla Province and Hwasun Countysecured 22.7 billion won in investment from six pharmaceutical and healthcare companies. South Jeolla Province and Hwasun County opened the two-day “2021 Hwasun International Vaccine Forum” at the Hanium Culture and Sports Center on the 4th. The forum, themed “The Status of Korean Vaccines in the Era of the COVID-19 Pandemic,” featured both on-site and online presentations. Director General Jerome Kim presented “From Pandemic to Endemic: Lessons Learned from the COVID-19 Outbreak for Global Vaccines.” Further presentations were given by Han-i Kim, CEO of the Light Fund; Professor Jeong Jae-hoon of Gachon University; Professor Kang Chang-yool of Seoul National University; and Seong Baek-rin, Director of the Vaccine Commercialization Technology Development Center. On the 5th, the International Society for Vaccines (ISV) International Conference will be held via video conference. Ahead of the opening of the 2021 Hwasun International Vaccine Forum, Hwasun County, together with South Jeolla Province, signed investment agreements with six domestic companies. The investment company Miracell Co., Ltd. (CEO Shin Hyeon-sun), The total investment is 22.7 billion won, including Brexogen Co., Ltd. (CEO Kim Soo), Jinmatrix Co., Ltd. (CEO Kim Soo-ok), Bioway Co., Ltd. (CEO Kim Jong-woo), Coscience Co., Ltd. (CEO Kim Seong-jun), and BC World Pharmaceutical Co., Ltd. (CEO Hong Seong-han). These companies have decided to invest in the Hwasun Vaccine Industrial Complex, including the construction of production facilities, and to actively foster local talent and expand employment. Bioway, a company specializing in anticancer drug development, will invest 10 billion won; Genematrix, a vaccine developer, will invest 4.5 billion won; Miracell and Brexogen, cell therapy and biopharmaceutical companies, will each invest 3 billion won; BC World Pharmaceutical, a pharmaceutical company, and Coscience, a bio-molecular diagnostics company, will each invest 1.2 billion won and 1 billion won, respectively. Hwasun County has been hosting the Hwasun International Vaccine Forum since 2016, attracting investment from domestic and international pharmaceutical and biotech companies. Furthermore, in March, the company signed a 30 billion won investment memorandum of understanding with Vaxcell Bio (Co-CEOs Lee Jun-haeng and Lee Je-joong). In April, the company also signed a contract to sell a 13,352 square meter factory site in the Hwasun Vaccine Industrial Complex. South Jeolla Province Governor Kim Young-rok emphasized, “We will establish a state-of-the-art medical complex and a large-scale production complex for world-class therapeutic vaccines to make South Jeolla Province a global biomedical hub.” Hwasun County Mayor Koo Chung-gon stated, “For South Korea to leap forward as one of the world’s top five vaccine powerhouses, we must foster Hwasun, Korea’s only vaccine industry special zone, as a true global vaccine hub and bio hub. I will do my best to ensure that Hwasun, a mecca for vaccines and biotechnology, plays a significant role in realizing our goal of becoming one of the top five vaccine powerhouses.” By Koo Gil-yong